Jonathon C Arnold
Biographic Data
| ID | 7372930 |
|---|---|
| NAME | Jonathon C Arnold |
| GIVEN NAMES | Jonathon C |
| FAMILY NAME | Arnold |
| SIGNATURE | ARNOLD J C |
| AFFILIATIONS | The University of Sydney |
| ORCID | 0000-0002-0159-9997 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-Fubinaca, Cumyl-Pinaca, PB-22, and XLR-11
These results suggest that while some "off-targets" could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted
Access to cannabidiol without a prescription
There are a variety of approaches in how countries manage access to CBD products. Many countries appear to permit OTC and online availability of CBD products but often without legislative clarity. As consumer demand for CBD escalates, improved legislation, guidelines and quality control of CBD products would seem prudent together with clinical trials exploring the therapeutic benefits of lower-dose CBD formulations
No prominent works on this page.
Access to cannabidiol without a prescription
There are a variety of approaches in how countries manage access to CBD products. Many countries appear to permit OTC and online availability of CBD products but often without legislative clarity. As consumer demand for CBD escalates, improved legislation, guidelines and quality control of CBD products would seem prudent together with clinical trials exploring the therapeutic benefits of lower-dose CBD formulations
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-Fubinaca, Cumyl-Pinaca, PB-22, and XLR-11
These results suggest that while some "off-targets" could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted
Cannabis and Cannabinoid Research (3 works) · Cannabinoid (2 works) · Cannabis (2 works) · Forensic Toxicology and Drug Analysis (2 works) · Medicine (2 works) · Pharmacology (2 works) · Psychiatry (2 works) · Synthetic cannabinoids (2 works) · Agency (philosophy (1 work) · Agonist (1 work)